title: Amiodarone: guidelines for use and monitoring.
abstract: Amiodarone is a potent antiarrhythmic agent that is used to treat ventricular arrhythmias and atrial fibrillation. The drug prevents the recurrence of life-threatening ventricular arrhythmias and produces a modest reduction of sudden deaths in high-risk patients. Amiodarone is more effective than sotalol or propafenone in preventing recurrent atrial fibrillation in patients for whom a rhythm-control strategy is chosen. When long-term amiodarone therapy is used, potential drug toxicity and interactions must be considered. The dosage of amiodarone should be kept at the lowest effective level. In patients who also are taking digoxin and warfarin, physicians must pay close attention to digoxin levels and prothrombin time, keeping in mind that the effects of interaction with amiodarone do not peak until seven weeks after the initiation of concomitant therapy. Laboratory studies to assess liver and thyroid function should be performed at least every six months.
authors.affiliation: Cardiac Electrophysiology Laboratory, York Hospital, York, Pennsylvania, USA. lsiddoway@post.harvard.edu
authors.forename: Lyle A
authors.initials: LA
authors.lastname: Siddoway
mesh_terms: D000638:Amiodarone / Q000009:adverse effects / Q000494:pharmacology*; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000494:pharmacology*; D004347:Drug Interactions; D006801:Humans
chemical_list: D000889:Anti-Arrhythmia Agents; D000638:Amiodarone